Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 e 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - agenti antineoplastici - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. solo sono disponibili dati limitati sull'efficacia e la sicurezza per i pazienti precedentemente trattati con anticorpi monoclonali tra rituximab o pazienti refrattari a precedenti rituximab più chemioterapia. vedere la sezione 5. 1 per ulteriori informazioni. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab ha dimostrato di ridurre il tasso di progressione del danno articolare misurato da x-ray e di migliorare la funzione fisica, quando somministrato in combinazione con metotressato. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - pantoprazolum - le compresse gastroresistenti di - pantoprazolum 40.00 mg ut pantoprazolum natricum sesquihydricum, natrii carbonas, mannitolum, crospovidonum, povidonum k 90, calcii stearas, Überzug: hypromellosum, povidonum k 25, e 171, e 172 (flavum), propylenglycolum, acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, triethylis citras, drucktinte: lacca, e 172 (rubrum), e 172 (nigrum), e 172 (flavum), ammoniae solutio concentrata, pro compresso obducto corresp. natrium 6.75 mg. - inibitori della pompa protonica - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - pantoprazolum - le compresse gastroresistenti di - pantoprazolum 20.00 mg ut pantoprazolum natricum sesquihydricum, natrii carbonas, mannitolum, crospovidonum, povidonum k 90, calcii stearas, Überzug: hypromellosum, povidonum k 25, e 171, e 172 (flavum), propylenglycolum, acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, triethylis citras, drucktinte: lacca, e 172 (rubrum), e 172 (nigrum), e 172 (flavum), ammoniae solutio concentrata, pro compresso obducto corresp. natrium 3.38 mg. - inibitori della pompa protonica - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - pantoprazolum - gastroresistenti compresse rivestite con film - pantoprazolum 20 mg ordine pantoprazolum natricum sesquihydricum, colore.: di e 104, e 124, excipiens pro compresso haze. - ulkustherapeutikum, protonenpumpenblocker - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - pantoprazolum - gastroresistenti compresse rivestite con film - pantoprazolum 40 mg ordine pantoprazolum natricum sesquihydricum, colore.: di e 104, e 124, excipiens pro compresso haze. - ulkustherapeutikum, protonenpumpenblocker - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - pantoprazolum - granulat - pantoprazolum 40 mg ordine pantoprazolum natricum sesquihydricum, excipiens annuncio granulatum, pro charta. - inibitori della pompa protonica - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

streuli pharma ag - pantoprazolum - compresse rivestite con film - pantoprazolum 20 mg ut pantoprazolum natricum sesquihydricum, maltitolum 38.425 mg, crospovidonum, carmellosum natricum, natrii carbonas, calcii stearas, Überzug: poly(alcohol vinylicus), talcum, e 171, macrogolum 3350, lecithinum, e 172 (flavum) natrii carbonas, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, triethylis citras, pro compresso obducto corresp. natrium 1.81 mg. - ulcustherapie, refluxoesophagitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

streuli pharma ag - pantoprazolum - filmabletten - pantoprazolum 40 mg ut pantoprazolum natricum sesquihydricum, maltitolum 76.85 mg, crospovidonum, carmellosum natricum, natrii carbonas, calcii stearas, Überzug: poly(alcohol vinylicus), talcum, e 171, macrogolum 3350, lecithinum, e 172 (flavum) natrii carbonas, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, triethylis citras, pro compresso obducto corresp. natrium 3.62 mg. - ulcustherapie, refluxoesophagitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - pantoprazolum - compresse rivestite con film - pantoprazolum 20 mg ordine pantoprazolum natricum sesquihydricum, excipiens pro compresso haze. - ulcustherapie, refluxoesophagitis - synthetika